Blog

We have captured this month's most interesting, innovative, and maybe some of the strangest examples of stem cells in the news from around the world.

September 2018 Go Everywhere with Bio-Techne Travel Grant Awarded to a Research Associate from Wayne State University!

Bio-Techne's Go Everywhere Travel Grant Program awards $1000 USD (or equivalent) to one researcher each month to attend the meeting of their choice. This grant program allows the researcher to attend more targeted meetings in their field and provides funding to support both small and large scientific associations that promote discovery and collaboration.

The recipient of the September 2018 grant is Dr. Samaresh Sau, a Research Associate in the Pharmaceutical Science department at Wayne State University in Detroit, Michigan (USA).

We have captured this month's most interesting, innovative, and maybe some of the strangest examples of stem cells in the news from around the world.

We have captured this month's most interesting, innovative, and maybe some of the strangest examples of stem cells in the news from around the world.

Watch this short video highlighting our CellXVivo™ kits developed for the consistent differentiation and expansion of T cells subtypes, dendritic cells, B cells, cytotoxic cells, and more. Kits include buffers, cytokines and optimized protocols for easy and reproducible cell culture.

Learn More About CellXVivo™ Immune Cell Differentiation and Expansion Kits

Recorded June 15, 2018

Myeloid-derived suppressor cells (MDSCs) are a diverse population of immature myeloid cells with immunosuppressive properties that accumulate under pathological conditions including specific types of cancer and infections. Two primary subsets of human and mouse MDSCs known as granulocytic and monocytic MDSCs have been identified. These cells are of great interest as high levels of circulating MDSCs in cancer patients have been shown to correlate with clinical stage, metastatic burden, and resistance to both chemotherapy and immunotherapy. As a result, MDSCs are now recognized as a major obstacle in the treatment of cancer. Multiple strategies targeting these cells are being investigated to determine if the...

Antibodies are critical tools in the majority of research and clinical studies. However, unreliable antibodies with poor specificity or reproducibility remain a significant drain on resources across biomedical research and industry. Widespread acceptance of the need for end-user antibody validation has led to high profile initiatives and guidance (e.g. Uhlen et al, Nat. Methods 2016). Aligning to these principles, the AstraZeneca Affinity Reagent Group provides company-wide advice and scientific support in the validation of both commercial and our bespoke antibodies generated in-house. Our work feeds into activities across the drug discovery pipeline, including target identification / validation, hit-...

Chemokine receptors and other multipass proteins require special consideration when staining live cells for flow cytometry analysis. These receptors have seven transmembrane domains, all of which are fluid and moving around in the cell membrane. As a result, the three extracellular loops, to which antibodies must bind, are also moving and this motion can change the orientation of antibody binding sites. While this domain flexibility is necessary for ligand binding to the receptor, it can create problems for flow cytometry staining of live cells. In addition to movement within the lipid membrane, chemokine receptors can undergo internalization and endocytic recycling,...

Researchers have long been attempting to identify and validate specific biomarkers for Alzheimer’s disease (AD). AD is a neurodegenerative disorder that is characterized by brain atrophy resulting from neuronal loss. It is typically diagnosed following a series of clinical assessments that include neurological and mental examinations and brain imaging. However, since many other disorders also display AD-like symptoms, the only way to definitively diagnosis AD is by tying clinical assessment of the disease to the postmortem identification of its pathological hallmarks (i.e. senile plaques...

Bio-Techne was pleased to be a sponsor of the 4^th Annual University of Minnesota Neuro-Oncology Symposium. The preclinical Provider/Researcher program included 4 sessions: Physics and Modeling, Blood Brain Barrier, Genetics, and Immunotherapy/Emerging Therapies.  The clinical Patient/Caregiver program included 2 sessions: Treatment & Therapies and Living with a Brain Tumor.

The Physics and Modeling Session focused mostly on cell culture model systems....

Bio-Techne’s Go Everywhere Travel Grant Program awards $1000 USD (or equivalent) to one researcher each month to attend the meeting of their choice. This grant program allows the researcher to attend more targeted meetings in their field and provides funding to support both small and large scientific associations that promote discovery and collaboration.

The recipient of the April 2018 grant is Linda Ban, a PhD Candidate in the Endocrinology department at the University of Sydney!

Linda has chosen to apply the grant to the ANZOS & Breakthrough Discoveries 2018 Joint Conference in Melbourne, Australia from October 16-18, 2018.

On January 2, 2018, Bio-Techne, the parent company of R&D Systems, proudly announced its acquisition of Atlanta Biologicals, Inc. As noted by Bio-Techne President and Chief Executive Officer, Charles R. Kummeth, "Atlanta Biologicals is a great fit with the Bio-Techne product portfolio as we continue to expand our cell culture and tissue regeneration capabilities. Many of our products are used in tissue culture applications and the Atlanta Biologicals fetal bovine serum (FBS) product line strengthens and complements our current tissue culture reagents offering and furthers our efforts to provide more complete solutions...